We’ve had to add a new tag… Alliances… because we don;t think this will be the last. St.Jude and Abbott’s “Choice Alliance” means they can both offer fuller bags in US contracts. Wonder how they’ll sort out the head to heads… I got there first. No I got there first.
Abbott
FDA Clears Abbott’s iFS Advanced Femtosecond Laser For Arcuate Incisions In Cataract Surgery
Femtosecond laser technology is fairly new to the ophthalmic surgical profession, especially in the US. Now FDA has cleared Abbott’s device for the creation of curved incisions in corneal surgery including cataract access.
Bioabsorbable Stent Data Says It’s Safe At 10 Years
Bioabsorbable stents are back in the news with the publication of ten year data from Japan claiming safety at ten years in a 50 patient study.
Japanese Approval For Abbott’s XIENCE PRIME™ Drug Eluting Stent
Achieving device approval in Japan is a major undertaking, so Abbott must be delighted that its Xience Prime everolimus eluting stent has got the nod based on a robust body of clinical evidence.
Everolimus Shines As Meta-Analysis Suggests Lower Thrombosis Rates Than Others
Everolimus stents appear top dog in long term stent thrombosis meta-analysis.
Abbott Previews Presentations Of Its Products At Forthcoming ACS Meeting
Abbott has published advance notice of presentations relating to its products at this year’s ACS congress which starts on Saturday 24th March.
Abbott’s Absolute Pro® Vascular Stent Receives FDA Approval For Iliac Artery Disease
Abbott’s Absolute Pro Stent for Iliac Disease has gained FDA clearance. The product is designed for precise stent placement and Optimal Flexibility to Conform to Challenging Lesions.
Abbott Sales Figures For Xience Stents Confirm Market Leadership According To Company
Abbott is sounding very pleased with itself about its drug-eluting stent sales figures, which it claims confirms its status as global market leader.
300 Stent Staff To Go At Abbott
Abbott Laboratories has announced that it will lay off 700 employees as part of ongoing restructuring efforts, 300 of the redundancies coming from the company’s Stent Division in Southern California.
J&J Loses Current Round In Drug Eluting Stent Patent Lawsuit With Medtronic, Abbott and Boston Scientific
You say sirolimus, I say everolimus… judge says lets call the whole thing off.
EVEREST II Study: MitraClip “May” Be Justified In High-Surgical-Risk Patients.
Results from “high-surgical-risk” study arm of MitraClip EVEREST II trial suggest the device does provide limited reduction in mitral regurgitation in patients for whom surgery is not an option.
FDA Wants Shrinkage Warning on Boston Scientific’s Newly Approved Promus Element™ Stent
Boston Scientific’s Promus Element Drug Eluting Stent was approved by FDA in late November and now the agency has demanded that the company includes a warning on its packaging about the risk of stent shrinkage.
Abbott Trials Absorb™ Bioresorbable Vascular Scaffold Against Metallic Drug Eluting Stent
Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company’s XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
Stent Shrinkage Still In Spotlight. FDA Wades In.
FDA is taking a proactive stance and working with manufacturers to understand the issue of longitudinal compression in next generation Drug-Eluting Stents.
Abbott Receives CE Mark for New Hepatitis Test
Abbott announced it has received CE Mark approval for its new, highly sensitive diagnostic test for detection of hepatitis B surface antigen.
Medtronic Resolute® Drug-Eluting Stent Shows Strong Results, Even in Challenging Diabetes Patients with Coronary Disease
Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device’s Consistently Positive Performance Across Multiple Clinical Studies